Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin

被引:196
作者
Pai, LH
Wittes, R
Setser, A
Willingham, MC
Pastan, I
机构
[1] NCI,NIH,MED BRANCH,BETHESDA,MD 20892
[2] MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425
关键词
D O I
10.1038/nm0396-350
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotoxin LMB-1 is composed of monoclonal antibody B3 chemically linked to PE38, a genetically engineered form of Pseudomonas exotoxin. B3 recognizes a carbohydrate antigen (Le(Y)) present on many human solid tumors(1). LMB-1 has excellent antitumor activity in nude mice bearing Le(Y)-positive tumors(2). We conducted a phase I study of 38 patients with solid tumors who failed conventional therapy and whose tumors expressed the Le(Y) antigen. Objective antitumor activity was observed in 5 patients, 18 had stable disease, 15 progressed. A complete remission was observed in a patient with metastatic breast cancer to supraclavicular nodes. A greater than 75% tumor reduction and resolution of all clinical symptoms lasting for more than six months was observed in a colon cancer patient with extensive retroperitoneal and cervical metastasis. Three patients (two colon, one breast cancer) had minor responses. The maximum tolerated dose of LMB-1 is 75 mu g/kg given intravenously three times every other day. The major toxicity is vascular leak syndrome manifested by hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary edema. Although immunotoxins have been evaluated in clinical studies for more than two decades, this is the first report of antitumor activity in epithelial tumors.
引用
收藏
页码:350 / 353
页数:4
相关论文
共 17 条
[1]   STRUCTURE OF EXOTOXIN-A OF PSEUDOMONAS-AERUGINOSA AT 3.0-ANGSTROM RESOLUTION [J].
ALLURED, VS ;
COLLIER, RJ ;
CARROLL, SF ;
MCKAY, DB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (05) :1320-1324
[2]   B3(FV)-PE38KDEL, A SINGLE-CHAIN IMMUNOTOXIN THAT CAUSES COMPLETE REGRESSION OF A HUMAN CARCINOMA IN MICE [J].
BRINKMANN, U ;
PAI, LH ;
FITZGERALD, DJ ;
WILLINGHAM, M ;
PASTAN, I .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (19) :8616-8620
[3]   TREATMENT OF B-CELL LYMPHOMAS WITH COMBINATION OF BISPECIFIC ANTIBODIES AND SAPORIN [J].
FRENCH, RR ;
HAMBLIN, TJ ;
BELL, AJ ;
TUTT, AL ;
GLENNIE, MJ .
LANCET, 1995, 346 (8969) :223-224
[4]   PHASE-I STUDY OF AN ANTI-BREAST CANCER IMMUNOTOXIN BY CONTINUOUS INFUSION - REPORT OF A TARGETED TOXIC EFFECT NOT PREDICTED BY ANIMAL STUDIES [J].
GOULD, BJ ;
BOROWITZ, MJ ;
GROVES, ES ;
CARTER, PW ;
ANTHONY, D ;
WEINER, LM ;
FRANKEL, AE .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (10) :775-781
[5]   FUNCTIONAL DOMAINS OF PSEUDOMONAS EXOTOXIN IDENTIFIED BY DELETION ANALYSIS OF THE GENE EXPRESSED IN ESCHERICHIA-COLI [J].
HWANG, J ;
FITZGERALD, DJ ;
ADHYA, S ;
PASTAN, I .
CELL, 1987, 48 (01) :129-136
[6]  
JAIN RK, 1988, CANCER RES, V48, P7022
[7]  
KONDO T, 1988, J BIOL CHEM, V263, P9470
[8]  
KUAN CT, IN PRESS CLIN CANC R
[9]   IMMUNOTOXIN THERAPY FOR CANCER [J].
PAI, LH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 269 (01) :78-81
[10]  
PAI LH, 1995, BIOL THERAPY CANC, P521